Author:
Cybulska Paulina,Hayes Sara A,Spirtos Alexandra,Rafizadeh Michael J,Filippova Olga T,Leitao Mario,Zivanovic Oliver,Sonoda Yukio,Mueller Jennifer,Lakhman Yuliya,Long Kara,Chi Dennis S
Abstract
ObjectivesTo assess outcomes and patterns of recurrence in patients with high-grade serous ovarian/tubal/primary peritoneal cancers with radiographic supraclavicular lymphadenopathy at diagnosis.MethodsWe evaluated all patients with newly diagnosed high-grade serous ovarian cancers treated at our center between January 1, 2008 and May 1, 2013 who had supraclavicular lymphadenopathy (defined as ≥1 cm in short axis) on radiographic imaging (either computed tomography or positron emission tomography) at the time of diagnosis.ResultsOf 586 patients with high-grade serous ovarian cancer receiving primary treatment during the study period, we identified 13 (2.2%) with supraclavicular lymphadenopathy diagnosed on pre-treatment imaging. The median age at diagnosis was 52.0 years (range 38.2–72.3). Five (31%) had clinically palpable nodes on physical examination. Four (31%) had a known BRCA mutation. All 13 patients underwent neoadjuvant chemotherapy, followed by interval debulking surgery. Each patient received a median of four cycles of neoadjuvant intravenous chemotherapy (range 3–7). At interval debulking surgery, complete gross resection was achieved in nine (70%) patients, and optimal resection (0.1–1 cm residual disease) in four (30%). Eleven patients (85%) recurred; however, only one (8%) recurred in the supraclavicular lymph nodes. Median follow-up time was 44.3 months (range 22.4–95.0). Median progression-free survival for the cohort was 11.7 months (95% CI 9.2 to 14.1). Median overall survival was 44.3 months (95% CI 41.5 to 47.1). In patients obtaining complete gross resection at interval debulking surgery, median progression-free survival and overall survival were 13.9 months (95% CI 8.9 to 18.9) and 78.1 months (95% CI 11.1 to 145.1), respectively.ConclusionsIn our study, approximately 2% of patients with high-grade serous ovarian cancer presented with radiographic evidence of supraclavicular lymphadenopathy. Supraclavicular lymphadenopathy at diagnosis did not portend an unfavorable outcome when complete gross resection was achieved at interval debulking surgery.
Funder
National Cancer Institute
Subject
Obstetrics and Gynecology,Oncology
Reference15 articles.
1. American Cancer Society
. Cancer Facts & Figures 2018, 2018. Available: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2018.html [Accessed 28 June 2018].
2. FIGO Committee on Gynecologic Oncology. staging classification for cancer of the ovary, fallopian tube, and peritoneum;Prat;Int J Gynaecol Obstet,2014
3. Howlader N
NA
,
Krapcho
M
,
Miller
D
. Seer cancer statistics review. 1975-2014 based on November 2016 SEER data submission, posted to the SEER web site, 2017. Available: https://seer.cancer.gov/csr/1975_2014/ [Accessed 28 Jun 2018].
4. Anatomy and histology of Virchow's node;Mizutani;Anat Sci Int,2005
5. Cervical lymph node metastases from remote primary tumor sites;López;Head Neck,2016
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献